ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of LY3053102 in Healthy Participants

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01736241
Recruitment Status : Completed
First Posted : November 29, 2012
Results First Posted : July 19, 2018
Last Update Posted : July 19, 2018
Sponsor:
Information provided by (Responsible Party):
Eli Lilly and Company

November 26, 2012
November 29, 2012
September 27, 2017
July 19, 2018
July 19, 2018
December 2012
July 2013   (Final data collection date for primary outcome measure)
Number of Participants With One or More Adverse Events (AEs) or Any Serious AEs [ Time Frame: Baseline through Day 31 ]
A summary of serious and other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.
Number of Participants With One or More Adverse Events (AEs) or Any Serious AEs [ Time Frame: Pre-dose up to Day 31 ]
Complete list of historical versions of study NCT01736241 on ClinicalTrials.gov Archive Site
  • Pharmacokinetics (PK): Area Under the Concentration Time Curve (AUC) of LY3053102 [ Time Frame: Time 0 to 168 hours after study drug administration on Day 1 ]
    AUC curve from time 0 to 168 hours postdose of LY3053102.
  • PK: Observed Maximum Drug Concentration (Cmax) of LY3053102 [ Time Frame: Time 0 to 168 hours after study drug administration on Day 1 ]
    Cmax of LY3053102 from time 0 to 168 hours after study drug administration on Day 1.
  • Number of Participants Who Developed Anti-LY3053102 Antibodies [ Time Frame: Baseline, up to Day 31 ]
    LY3053102 anti-drug antibodies (ADA) were assessed at baseline, 15 and 29 days. The number of participants with an initial postbaseline positive titer (defined as a >=2-fold increase in the ADA titer from baseline) anti-drug (LY3053102) ADA at each time point were summarized.
  • Pharmacokinetics (PK): Area Under the Concentration Curve (AUC) of LY3053102 [ Time Frame: Pre-dose up to Day 31 ]
  • Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY3053102 [ Time Frame: Pre-dose up to Day 31 ]
  • Number of Participants Developing Anti-LY3053102 Antibodies [ Time Frame: Pre-dose up to Day 31 ]
Not Provided
Not Provided
 
A Study of LY3053102 in Healthy Participants
A Single-Dose, Dose-Escalation Study to Determine the Safety, Tolerability, and Pharmacokinetics of LY3053102 in Healthy Subjects
The main purpose of this study was to evaluate the safety and tolerability of the study drug known as LY3053102 in healthy participants. The study also investigated how much of the study drug entered the blood stream and how long it took the body to dispose of the study drug. Information about any side effects that occurred was also collected. The study was expected to last approximately 8 weeks for each participant (up to 4 weeks from screening to the administration of study drug and an additional 4 weeks of follow up).
Not Provided
Interventional
Phase 1
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Basic Science
Healthy Volunteers
  • Drug: LY3053102
  • Drug: Placebo
  • Experimental: LY3053102
    A single 2-, 7-, 20-, 50-, 150-, or 405-milligrams (mg) dose of LY3053102 was subcutaneously administered to newly randomized participants in 6 escalating dose level cohorts. The dose was escalated based on the safety results over at least a 7-day evaluation period postdose. The dose escalation occurred over 13 weeks proceeding according to tolerability at each dose level.
    Intervention: Drug: LY3053102
  • Placebo Comparator: Placebo
    A single dose of LY3053102-matching placebo was administered subcutaneously to 1 newly randomized participant in each LY3053102-dose level cohort over 13 weeks.
    Intervention: Drug: Placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
41
53
July 2013
July 2013   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Normal blood pressure
  • Female participants were not of child-bearing potential due to surgical sterilization (hysterectomy or bilateral oophorectomy or tubal ligation) or menopause
  • Had a body mass index (BMI) of 18.5 to 40.0 kilograms per square meter (kg/m^2), inclusive, at screening

Exclusion Criteria:

  • Had known allergies to LY3053102 or related compounds
  • Had a history of significant disease that may have affected the actions of drugs or may pose a risk when taking the study medication
  • Had a history of developing allergies, asthma, severe drug allergies (symptoms including, but not limited to, itching, red rashes, sores on the skin, scaling and shedding of skin), allergies or reactions to more than one drug, or have had bad reactions to skin creams containing corticosteroids
  • Heavy smokers (more than 10 cigarettes a day)
Sexes Eligible for Study: All
21 Years to 65 Years   (Adult, Older Adult)
Yes
Contact information is only displayed when the study is recruiting subjects
Singapore
 
 
NCT01736241
14514
I6I-MC-LMRA ( Other Identifier: Eli Lilly and Company )
No
Not Provided
Not Provided
Eli Lilly and Company
Eli Lilly and Company
Not Provided
Study Director: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST) Eli Lilly and Company
Eli Lilly and Company
September 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP